For how we live.
US guidelines recommend routine chlamydia and gonorrhea screening for sexually active women under 25 and older women at higher risk. Self-collected swabs match clinician-collected ones closely.
Most women have a recurrence within a year of standard treatment. A 2025 trial stopped early once treating a woman alone proved inferior to treating her and her male partner together.
Years of observational data suggested 4CMenB cut gonorrhea risk by a third or more. A placebo-controlled trial in 654 people at high risk found essentially no effect at all.
Rated against other symptom-management strategies women already use, masturbation scored among the highest for relieving mood changes and sleep disturbance. Nearly half said they'd try it if a doctor suggested it.
Zoliflodacin is the first antibiotic developed solely for gonorrhoea in decades, and a non-profit holds the rights to register it across most of the world.
New EGASP surveillance data released for World AMR Awareness Week show cefixime resistance up from 1.7% to 11% and ciprofloxacin resistance at 95% across 12 reporting countries.